• Publications
  • Influence
The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin
Renal OCT1 expression may be important not only in relation to metformin but with respect to other drugs as well, and increased renal clearance, in parallel with the known decreased hepatic uptake, may contribute to reduced met formin efficacy in low‐activity genotypes. Expand
Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver
Results suggest that CBR1 is a predominant hepatic DOX reductase, and the variability in the CBR 1 expression may affect outcomes of therapies with DOX, as well as with otherCBR1 substrates. Expand
Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration.
OCT1 plays an important role in the hepatocellular uptake of morphine and carriers of loss-of-function OCT1 polymorphisms may be at higher risk of adverse effects after codeine administration, especially if they are also ultra-rapid CYP2D6 metabolizers. Expand
Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative.
The presented technique can easily performed with an isocratic HPLC apparatus and provides highly specific results for MDA as do sophisticated GC-MS methods. Expand
Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron
OCT1 deficiency may increase efficacy of tropisetron and potentially of ondansetron by limiting their hepatic uptake, in addition to the known effects of CYP2D6. Expand
Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
Tolbutamide was confirmed as a substrate of the genetically polymorphic enzyme CYP2C9, and the pronounced differences in pharmacokinetics due to the amino acid variants did not significantly affect plasma insulin and glucose concentrations in healthy volunteers. Expand
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
Bupropion is applied in depression and smoking cessation. Genetic polymorphisms in cytochrome P450 2B6 (CYP2B6) may cause variability in bupropion pharmacokinetics since hydroxylation is known to beExpand
Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2
According to in vitro data, the polymorphic cytochrome P450 enzyme 2C9 (CYP2C9) may be the major S‐ibuprofen hydroxylase. In humans, there are 2 variants of CYP2C9 with a high population frequency.Expand
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype
The role of the CYP2C8*3 allele coding for the Arg139Lys and Lys399Arg amino acid substitutions is clarified with regard to the pharmacokinetics and clinical effects of rosiglitazone. Expand
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers
It is hypothesized that glyburide may be a substrate of cytochrome P450 2C9 (CYP2C9), an enzyme that has two low‐activity amino acid variants‐Arg144Cys and Ile359Leu and the impact of these polymorphisms on glyBuride pharmacokinetics and the effects on insulin and glucose concentrations is explored. Expand